Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 600 participants.

Also called NCT06337175

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 600 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06337175
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06337175. Non-randomized; no masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2023-10-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction
Condition
Alteplase Adverse Reaction
Intervention (Drug)
Alteplase
Intervention (Drug)
Alteplase
Lead sponsor
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct06337175
Content hash
403f4934f27ffbe51a41dca919ef9d31eb41e4f5a1e54ab9313efaf59ad4bd32